Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CISD1 | Q9NZ45 | 3/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA3 | P07451 | 1/20 | 0.49 |
| ▸ | CA4 | P22748 | 1/20 | 0.49 |
| ▸ | CA6 | P23280 | 1/20 | 0.49 |
| ▸ | CA5A | P35218 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.49 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8574555 | 0.86 | CA12 (0.53) | CISD1CA12CA1CA2CA3 | |
| SCHEMBL31704495 | 0.85 | CA12 (0.51) | CA12CA1CA2CA3CA4 | |
| SCHEMBL3201757 | 0.84 | CISD1 (0.50) | CISD1CA12CA1CA2CA3 | |
| SCHEMBL8573459 | 0.84 | CA12 (0.68) | CISD1CA12CA1CA2CA3 | |
| SCHEMBL2876194 | 0.83 | CISD1 (0.72) | CISD1CA12CA1CA2CA3 | |
| SCHEMBL13544474 | 0.82 | APP (0.50) | CISD1CA12CA1CA2CA3 | |
| SCHEMBL6674304 | 0.81 | CISD1 (0.50) | CISD1CA12CA1CA2CA3 | |
| SCHEMBL31401278 | 0.81 | ALDH1A1 (0.42) | LMNAALDH1A1 | |
| SCHEMBL13544481 | 0.80 | ATM (0.48) | CISD1CA12CA1CA2CA3 | |
| SCHEMBL13544476 | 0.80 | KDM4E (0.52) | CISD1CA12CA1CA2CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025215115-A1 | COMPOUNDS FOR USE THE TREATMENT OF CANCER, NEURODEGENERATIVE DISEASES, PSYCHIATRIC DISORDERS, INFLAMMATION, EPILEPSY AND SEIZURES | B&A ONCOMEDICAL (FR) | 2025-10-16 | — | — | WO | disclosed |
| US-20020147337-A1 | Process for preparing sulfonylcarboxamide derivatives | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-10-10 | — | — | US | disclosed |
| WO-2002072538-A1 | IMPROVED METHOD FOR PRODUCING SULFONYL CARBOXAMIDE DERIVATIVES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-09-19 | — | — | WO | disclosed |
| EP-0699666-B1 | Heterocyclic substituted benzoylguanidine | MERCK PATENT GMBH (DE) | 1999-01-07 | — | — | EP | disclosed |
| US-5753680-A | Heterocyclyl-benzoylguanidines | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1998-05-19 | — | — | US | disclosed |
| EP-0699666-A1 | Heterocyclic substituted benzoylguanidine | MERCK PATENT GmbH (DE) | 1996-03-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147337-A1 | Process for preparing sulfonylcarboxamide derivatives | SLC5A1, CES1, SLC5A2 | CISD1 730/4885CA12 3364/4885CA1 2359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.